Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Bristow, M F
and
Kohen, D
1993.
How "malignant" is the neuroleptic malignant syndrome?.
BMJ,
Vol. 307,
Issue. 6914,
p.
1223.
Dalgleish, A G
1993.
Human T cell leukaemia/lymphoma virus and blood donation..
BMJ,
Vol. 307,
Issue. 6914,
p.
1224.
Shaw, A.
and
Matthews, E.E.
1995.
Postoperative neuroleptic malignant syndrome.
Anaesthesia,
Vol. 50,
Issue. 3,
p.
246.
Buckley, P F
and
Hutchinson, M
1995.
Neuroleptic malignant syndrome..
Journal of Neurology, Neurosurgery & Psychiatry,
Vol. 58,
Issue. 3,
p.
271.
Looi, Jeffrey C.L.
Cubis, Jeffrey C.
and
Saboisky, John
1995.
Hyponatremia, Convulsions and Neuroleptic Malignant Syndrome in a Male with Schizoaffective Disorder.
Australian & New Zealand Journal of Psychiatry,
Vol. 29,
Issue. 4,
p.
683.
Lear, J T
and
English, J S
1996.
Toxic epidermal necrolysis associated with indomethacin therapy.
Postgraduate Medical Journal,
Vol. 72,
Issue. 845,
p.
186.
Singh, R
and
Hassanally, D
1996.
Neuroleptic malignant syndrome with normal creatine kinase.
Postgraduate Medical Journal,
Vol. 72,
Issue. 845,
p.
187.
Kohen, D.
and
Bristow, M.
1996.
Neuroleptic malignant syndrome.
Advances in Psychiatric Treatment,
Vol. 2,
Issue. 4,
p.
151.
WELLER, M.
and
KORNHUBER, J.
1996.
Clozapine‐induced neuroleptic malignant syndrome: another inconclusive case report.
Australian and New Zealand Journal of Medicine,
Vol. 26,
Issue. 2,
p.
232.
Fitzgerald, B.
Middleton, J. K.
and
Cooper, S.-A.
1997.
Adverse effects of summer amongst people with learning disabilities: neuroleptic malignant syndrome.
Journal of Intellectual Disability Research,
Vol. 41,
Issue. 3,
p.
273.
Fitzgerald, B.
Middleton, J. K.
and
Cooper, S.‐A.
1997.
Adverse effects of summer amongst people with learning disabilities: neuroleptic malignant syndrome.
Journal of Intellectual Disability Research,
Vol. 41,
Issue. 3,
p.
273.
Williams, Kelwyn
and
MacPherson, Rob
1997.
Reintroduction of antipsychotics in a patient with clozapine induced neuroleptic malignant syndrome.
Irish Journal of Psychological Medicine,
Vol. 14,
Issue. 4,
p.
147.
Nyfort-Hansen, Karin
and
Alderman, Christopher P
2000.
Possible Neuroleptic Malignant Syndrome Associated with Olanzapine.
Annals of Pharmacotherapy,
Vol. 34,
Issue. 5,
p.
667.
Aydin, N
Anaç, A
Çayköylü, A
and
Akçay, F
2001.
Reply: Citalopram Overdose, Serotonin Toxicity, or Neuroleptic Malignant Syndrome?.
The Canadian Journal of Psychiatry,
Vol. 46,
Issue. 7,
p.
658.
Kodatsch, Irmgard
Finsterer, J.
and
Stöllberger, Claudia
2001.
Serum Creatine Kinase Elevation in a Medical Department.
Acta Medica Austriaca,
Vol. 28,
Issue. 1,
p.
11.
Weller, Michael
and
Lehmann-Horn, Frank
2003.
Neurological Disorders.
p.
783.
D’Eufemia, Patrizia
Celli, Mauro
Zambrano, Anna
and
Finocchiaro, Roberto
2016.
Biomarkers in Bone Disease.
p.
1.
D’Eufemia, Patrizia
Celli, Mauro
Zambrano, Anna
and
Finocchiaro, Roberto
2017.
Biomarkers in Bone Disease.
p.
177.
Singh, Ram Sarup
Singh, Taranjeet
and
Singh, Ashish Kumar
2019.
Advances in Enzyme Technology.
p.
225.
Bokern, Hein
Jonker, Niels
and
Cohen, Dan
2021.
Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour.
BJPsych Open,
Vol. 7,
Issue. 1,